Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
Siteman Cancer Center, St. Louis, MO 63108, USA.
Int J Mol Sci. 2023 May 14;24(10):8739. doi: 10.3390/ijms24108739.
Molecules involved in drug resistance can be targeted for better therapeutic efficacies. Research on midkine (MDK) has escalated in the last few decades, which affirms a positive correlation between disease progression and MDK expression in most cancers and indicates its association with multi-drug resistance in cancer. MDK, a secretory cytokine found in blood, can be exploited as a potent biomarker for the non-invasive detection of drug resistance expressed in various cancers and, thereby, can be targeted. We summarize the current information on the involvement of MDK in drug resistance, and transcriptional regulators of its expression and highlight its potential as a cancer therapeutic target.
参与耐药的分子可以作为靶点,以提高治疗效果。过去几十年,中期因子(MDK)的研究进展迅速,这证实了在大多数癌症中,疾病进展与 MDK 表达之间存在正相关关系,并表明其与癌症的多药耐药性有关。MDK 是一种在血液中发现的分泌细胞因子,可作为各种癌症中表达的耐药性的非侵入性检测的有效生物标志物加以利用,因此可以作为靶向治疗的靶点。我们总结了目前关于 MDK 参与耐药性的信息,以及其表达的转录调节因子,并强调了它作为癌症治疗靶点的潜力。